BRAF and melanoma: A recent report showed that translocation of the entire ERK signaling pathway to endoplasmic reticulum could drive therapy resistance in BRAF-mutant melanoma [72], indicating a therapeutic potential of simultaneous targeting of ER and BRAF in melanoma.